Advertisement

Use of herbal supplements for chronic liver disease

Published:October 28, 2004DOI:https://doi.org/10.1016/S1542-3565(04)00455-0
      Background & Aims: Complementary and alternative medicine (CAM) is becoming popular among patients with liver disease. Although there is a growing body of evidence regarding potential mechanisms of action of these and other herbs, caution must be used to interpret the results of the few clinical trials available. Our goal was to discuss the biologic rationale for the use of specific herbs (silymarin, glycyrrhizin, sho-saiko-to, Phyllanthus amarus, Picrorrhiza kurroa, Compound 861, CH-100, and LIV.52) in the treatment of chronic liver diseases, as well as the evidence for their efficacy and adverse effects according to clinical trials. Methods: Because of the relative paucity of clinical studies using herbs, every trial published in English was reviewed. Results: Although many trials suggest that these herbs can decrease serum transaminase levels, the effects on hepatic histopathology and long-term survival are either poorly studied or conflicting. LIV.52 has been withdrawn from the market because of deleterious effects in patients with liver disease. Conclusions: Based on current evidence, we cannot recommend the use of herbal supplements for the routine treatment of any chronic liver disease and further well-designed clinical trials are necessary.

      Abbreviation used in this paper:

      CAM (complementary and alternative medicine)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Eisenberg D.M.
        • Kessler R.C.
        • Foster C.
        • Norlock F.E.
        • Calkins D.R.
        • Delbanco T.L.
        Unconventional medicine in the United States. Prevalence, costs, and patterns of use.
        N Engl J Med. 1993; 328: 246-252
        • Cohen M.R.
        Herbal and complementary and alternative medicine therapies for liver disease. A focus on Chinese traditional medicine in hepatitis C virus.
        Clin Liver Dis. 2001; 5 (vii.): 461-478
        • Eisenberg D.M.
        • Davis R.B.
        • Ettner S.L.
        • Appel S.
        • Wilkey S.
        • Van Rompay M.
        • Kessler R.C.
        Trends in alternative medicine use in the United States, 1990–1997.
        JAMA. 1998; 280: 1569-1575
        • Seeff L.B.
        • Lindsay K.L.
        • Bacon B.R.
        • Kresina T.F.
        • Hoofnagle J.H.
        Complementary and alternative medicine in chronic liver disease.
        Hepatology. 2001; 34: 595-603
        • Strader D.B.
        • Bacon B.R.
        • Lindsay K.L.
        • La Brecque D.R.
        • Morgan T.
        • Wright E.C.
        • Allen J.
        • Khokar M.F.
        • Hoofnagle J.H.
        • Seeff L.B.
        Use of complementary and alternative medicine in patients with liver disease.
        Am J Gastroenterol. 2002; 97: 2391-2397
        • Pepping J.
        Milk thistle.
        Am J Health Syst Pharm. 1999; 56: 1195-1197
        • Mira L.
        • Silva M.
        • Manso C.F.
        Scavenging of reactive oxygen species by silibinin dihemisuccinate.
        Biochem Pharmacol. 1994; 48: 753-759
        • Pietrangelo A.
        • Borella F.
        • Casalgrandi G.
        • Montosi G.
        • Ceccarelli D.
        • Gallesi D.
        • Giovannini F.
        • Gasparetto A.
        • Masini A.
        Antioxidant activity of silybin in vivo during long-term iron overload in rats.
        Gastroenterology. 1995; 109: 1941-1949
        • Carini R.
        • Comoglio A.
        • Albano E.
        • Poli G.
        Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016.
        Biochem Pharmacol. 1992; 43: 2111-2115
        • Sonnenbichler J.
        • Zetl I.
        Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers.
        Prog Clin Biol Res. 1986; 213: 319-331
        • Fiebrich F.
        • Koch H.
        Silymarin, an inhibitor of lipoxygenase.
        Experientia. 1979; 35: 1548-1560
        • Dehmlow C.
        • Erhard J.
        • de Groot H.
        Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin.
        Hepatology. 1996; 23: 749-754
        • Boigk G.
        • Stroedter L.
        • Herbst H.
        • Waldschmidt J.
        • Riecken E.O.
        • Schuppan D.
        Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats.
        Hepatology. 1997; 26: 643-649
        • Zi X.
        • Grasso A.W.
        • Kung H.J.
        • Agarwal R.
        A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
        Cancer Res. 1998; 58: 1920-1929
        • Zi X.
        • Feyes D.K.
        • Agarwal R.
        Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468.
        Clin Cancer Res. 1998; 4: 1055-1064
        • Hakov’a H.
        • Misurova E.
        The effect of silymarin and gamma radiation on nucleic acids in rat organs.
        J Pharm Pharmacol. 1993; 45: 910-912
        • Venkataramanan R.
        • Ramachandran V.
        • Komoroski B.J.
        • Zhang S.
        • Schiff P.L.
        • Strom S.C.
        Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures.
        Drug Metab Dispos. 2000; 28: 1270-1273
        • Wagner H.
        • Diesel P.
        • Seitz M.
        The chemistry and analysis of silymarin from Silybum marianum Gaertn.
        Arzneimittelforschung. 1974; 24: 466-471
        • Hruby K.
        • Csomos G.
        • Fuhrmann M.
        • Thaler H.
        Chemotherapy of Amanita phalloides poisoning with intravenous silibinin.
        Hum Toxicol. 1983; 2: 183-195
        • Ferenci P.
        • Dragosics B.
        • Dittrich H.
        • Frank H.
        • Benda L.
        • Lochs H.
        • Meryn S.
        • Base W.
        • Schneider B.
        Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.
        J Hepatol. 1989; 9: 105-113
        • Pares A.
        • Planas R.
        • Torres M.
        • Caballeria J.
        • Viver J.M.
        • Acero D.
        • Panes J.
        • Rigau J.
        • Santos J.
        • Rodes J.
        Effects of silymarin in alcoholic patients with cirrhosis of the liver.
        J Hepatol. 1998; 28: 615-621
        • Angulo P.
        • Patel T.
        • Jorgensen R.A.
        • Therneau T.M.
        • Lindor K.D.
        Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
        Hepatology. 2000; 32: 897-900
        • Adverse Drug Reactions Advisory Committee
        An adverse reaction to the herbal medication milk thistle (Silybum marianum).
        Med J Aust. 1999; 170: 218-219
        • van Rossum T.G.
        • Vulto A.G.
        • Hop W.C.
        • Schalm S.W.
        Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection.
        Clin Ther. 1999; 21: 2080-2090
        • Yoshikawa M.
        • Matsui Y.
        • Kawamoto H.
        • Umemoto N.
        • Oku K.
        • Koizumi M.
        • Yamao J.
        • Kuriyama S.
        • Nakano H.
        • Hozumi N.
        • Ishizaka S.
        • Fukui H.
        Effects of glycyrrhizin on immune-mediated cytotoxicity.
        J Gastroenterol Hepatol. 1997; 12: 243-248
        • Shiki Y.
        • Ishikawa Y.
        • Shirai K.
        • Saito Y.
        • Yoshida S.
        Effect of glycyrrhizin on lysosomes labilization by phospholipase A2.
        Am J Chin Med. 1986; 14: 131-137
        • Shiki Y.
        • Shirai K.
        • Saito Y.
        • Yoshida S.
        • Mori Y.
        • Wakashin M.
        Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody.
        J Gastroenterol Hepatol. 1992; 7: 12-16
        • Crance J.M.
        • Leveque F.
        • Biziagos E.
        • van Cuyck-Gandre H.
        • Jouan A.
        • Deloince R.
        Studies on mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro.
        Antiviral Res. 1994; 23: 63-76
        • van Rossum T.G.
        • Vulto A.G.
        • de Man R.A.
        • Brouwer J.T.
        • Schalm S.W.
        Review article.
        Aliment Pharmacol Ther. 1998; 12: 199-205
        • Abe N.
        • Ebina T.
        • Ishida N.
        Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice.
        Microbiol Immunol. 1982; 26: 535-539
        • Yoshioka K.
        • Kakumu S.
        • Arao M.
        • Tsutsumi Y.
        • Inoue M.
        Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease.
        Hepatology. 1989; 10: 769-773
        • Marinos G.
        • Naoumov N.V.
        • Rossol S.
        • Torre F.
        • Wong P.Y.
        • Gallati H.
        • Portmann B.
        • Williams R.
        Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection.
        Gastroenterology. 1995; 108: 1453-1463
        • Takahara T.
        • Watanabe A.
        • Shiraki K.
        Effects of glycyrrhizin on hepatitis B surface antigen.
        J Hepatol. 1994; 21: 601-609
        • Stewart P.M.
        • Wallace A.M.
        • Valentino R.
        • Burt D.
        • Shackleton C.H.
        • Edwards C.R.
        Mineralocorticoid activity of liquorice.
        Lancet. 1987; 2: 821-824
        • Arase Y.
        • Ikeda K.
        • Murashima N.
        • Chayama K.
        • Tsubota A.
        • Koida I.
        • Suzuki Y.
        • Saitoh S.
        • Kobayashi M.
        • Kumada H.
        The long term efficacy of glycyrrhizin in chronic hepatitis C patients.
        Cancer. 1997; 79: 1494-1500
        • Tarao K.
        • Rino Y.
        • Ohkawa S.
        • Shimizu A.
        • Tamai S.
        • Miyakawa K.
        • Aoki H.
        • Imada T.
        • Shindo K.
        • Okamoto N.
        • Totsuka S.
        Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis.
        Cancer. 1999; 86: 589-595
        • Xianshi S.
        • Huiming C.
        • Lizhuang W.
        • Chuanfa J.
        • Jianhui L.
        Clinical and laboratory observation on the effect of glycyrrhizin in acute and chronic viral hepatitis.
        J Tradit Chin Med. 1984; 4: 127-132
        • Shimizu I.
        • Ma Y.R.
        • Mizobuchi Y.
        • Liu F.
        • Miura T.
        • Nakai Y.
        • Yasuda M.
        • Shiba M.
        • Horie T.
        • Amagaya S.
        • Kawada N.
        • Hori H.
        • Ito S.
        Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats.
        Hepatology. 1999; 29: 149-160
        • Sakaida I.
        • Matsumura Y.
        • Akiyama S.
        • Hayashi K.
        • Ishige A.
        • Okita K.
        Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined diet.
        J Hepatol. 1998; 28: 298-306
        • Kakumu S.
        • Yoshioka K.
        • Wakita T.
        • Ishikawa T.
        Effects of TJ-9 Sho-saiko-to (kampo medicine) on interferon gamma and antibody production specific for hepatitis B virus antigen in patients with type B chronic hepatitis.
        Int J Immunopharmacol. 1991; 13: 141-146
        • Yamashiki M.
        • Nishimura A.
        • Suzuki H.
        • Sakaguchi S.
        • Kosaka Y.
        Effects of the Japanese herbal medicine “Sho-saiko-to” (TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C.
        Hepatology. 1997; 25: 1390-1397
        • Matsuzaki Y.
        • Kurokawa N.
        • Terai S.
        • Matsumura Y.
        • Kobayashi N.
        • Okita K.
        Cell death induced by baicalein in human hepatocellular carcinoma cell lines.
        Jpn J Cancer Res. 1996; 87: 170-177
        • Yano H.
        • Mizoguchi A.
        • Fukuda K.
        • Haramaki M.
        • Ogasawara S.
        • Momosaki S.
        • Kojiro M.
        The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase.
        Cancer Res. 1994; 54: 448-454
        • Hirayama C.
        • Okumura M.
        • Tanikawa K.
        • Yano M.
        • Mizuta M.
        • Ogawa N.
        A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis.
        Gastroenterol Jpn. 1989; 24: 715-719
        • Tajiri H.
        • Kozaiwa K.
        • Ozaki Y.
        • Miki K.
        • Shimuzu K.
        • Okada S.
        Effect of sho-saiko-to (xiao-chai-hu-tang) on HBeAg clearance in children with chronic hepatitis B virus infection and with sustained liver disease.
        Am J Chin Med. 1991; 19: 121-129
        • Oka H.
        • Yamamoto S.
        • Kuroki T.
        • Harihara S.
        • Marumo T.
        • Kim S.R.
        • Monna T.
        • Kobayashi K.
        • Tango T.
        Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9).
        Cancer. 1995; 76: 743-749
        • Kiguchi T.
        • Kimura F.
        • Niiya K.
        • Katayama Y.
        • Harada M.
        Acute thrombocytopenic purpura after ingestion of Sho-saiko-to for hepatitis.
        Liver. 2000; 20: 491
        • Kamiyama T.
        • Nouchi T.
        • Kojima S.
        • Murata N.
        • Ikeda T.
        • Sato C.
        Autoimmune hepatitis triggered by administration of an herbal medicine.
        Am J Gastroenterol. 1997; 92: 703-704
        • Katou K.
        • Mori K.
        Autoimmune hepatitis with drug-induced pneumonia due to Sho-saiko-to.
        Nihon Kokyuki Gakkai Zasshi. 1999; 37: 641-646
        • Itoh S.
        • Marutani K.
        • Nishijima T.
        • Matsuo S.
        • Itabashi M.
        Liver injuries induced by herbal medicine, sho-saiko-to (xiao-chai-hu-tang).
        Dig Dis Sci. 1995; 40: 1845-1848
        • Murakami K.
        • Okajima K.
        • Sakata K.
        • Takatsuki K.
        A possible mechanism of interstitial pneumonia during interferon therapy with sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi.
        Japanese Journal of Thoracic Diseases. 1995; 33: 389-394
        • Blumberg B.S.
        • Millman I.
        • Venkateswaran P.S.
        • Thyagarajan S.P.
        Hepatitis B virus and primary hepatocellular carcinoma.
        Vaccine. 1990; 8: S86-S92
        • Ott M.
        • Thyagarajan S.P.
        • Gupta S.
        Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors.
        Eur J Clin Invest. 1997; 27: 908-915
        • Lee C.D.
        • Ott M.
        • Thyagarajan S.P.
        • Shafritz D.A.
        • Burk R.D.
        • Gupta S.
        Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication.
        Eur J Clin Invest. 1996; 26: 1069-1076
        • Yeh S.F.
        • Hong C.Y.
        • Huang Y.L.
        • Liu T.Y.
        • Choo K.B.
        • Chou C.K.
        Effect of an extract from Phyllanthus amarus on hepatitis B surface antigen gene expression in human hepatoma cells.
        Antiviral Res. 1993; 20: 185-192
        • Thyagarajan S.P.
        • Subramanian S.
        • Thirunalasundari T.
        • Venkateswaran P.S.
        • Blumberg B.S.
        Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus.
        Lancet. 1988; 2: 764-766
        • Liu J.
        • Lin H.
        • McIntosh H.
        Genus Phyllanthus for chronic hepatitis B virus infection.
        J Viral Hepat. 2001; 8: 358-366
        • Leelarasamee A.
        • Trakulsomboon S.
        • Maunwongyathi P.
        • Somanabandhu A.
        • Pidetcha P.
        • Matrakool B.
        • Lebnak T.
        • Ridthimat W.
        • Chandanayingyong D.
        Failure of Phyllanthus amarus to eradicate hepatitis B surface antigen from symptomless carriers.
        Lancet. 1990; 335: 1600-1601
        • Berk L.
        • de Man R.A.
        • Schalm S.W.
        • Labadie R.P.
        • Heijtink R.A.
        Beneficial effects of Phyllanthus amarus for chronic hepatitis B, not confirmed.
        J Hepatol. 1991; 12: 405-406
        • Thamlikitkul V.
        • Wasuwat S.
        • Kanchanapee P.
        Efficacy of Phyllanthus amarus for eradication of hepatitis B virus in chronic carriers.
        J Med Assoc Thai. 1991; 74: 381-385
        • Milne A.
        • Hopkirk N.
        • Lucas C.R.
        • Waldon J.
        • Foo Y.
        Failure of New Zealand hepatitis B carriers to respond to Phyllanthus amarus.
        N Z Med J. 1994; 107: 243
        • Xin-Hua W.
        • Chang-Qing L.
        • Xing-Bo G.
        • Lin-Chun F.
        A comparative study of Phyllanthus amarus compound and interferon in the treatment of chronic viral hepatitis B.
        Southeast Asian J Trop Med Public Health. 2001; 32: 140-142
        • Luper S.
        A review of plants used in the treatment of liver disease.
        Altern Med Rev. 1998; 3: 410-421
        • Rajeshkumar N.V.
        • Kuttan R.
        Protective effect of Picroliv, the active constituent of Picrorrhiza kurroa, against chemical carcinogenesis in mice.
        Teratog Carcinog Mutagen. 2001; 21: 303-313
        • Mehrotra R.
        • Rawat S.
        • Kulshreshtha D.K.
        • Patnaik G.K.
        • Dhawan B.N.
        In vitro studies on the effect of certain natural products against hepatitis B virus.
        Indian J Med Res. 1990; 92: 133-138
        • Chander R.
        • Kapoor N.K.
        • Dhawan B.N.
        Picroliv, picroside-I and kutkoside from Picrorrhiza kurrooa are scavengers of superoxide anions.
        Biochem Pharmacol. 1992; 44: 180-183
        • Pandey B.L.
        • Das P.K.
        Immunopharmacological studies on Picrorrhiza kurroa Royle-ex-Benth. Part IV: cellular mechanisms of anti-inflammatory action.
        Indian J Physiol Pharmacol. 1989; 33: 28-30
        • Vaidya A.B.
        • Antarkar D.S.
        • Doshi J.C.
        • Bhatt A.D.
        • Ramesh V.
        • Vora P.V.
        • Perissond D.
        • Baxi A.J.
        • Kale P.M.
        Picrorrhiza kurroa (Kutaki) Royle ex Benth as a hepatoprotective agent—experimental & clinical studies.
        J Postgrad Med. 1996; 42: 105-108
        • Jia J.D.
        • Wang B.E.
        • Dong Z.
        • Cui L.
        • Zhu J.X.
        • Che J.T.
        The effect of herbal compound 861 on mRNA levels for type I, III and IV collagens and TGF in immune complex rat liver fibrosis.
        Chin J Hepatol. 1996; 4: 214-216
        • You H.
        • Wang B.
        • Wang T.
        • Ma X.
        • Zhang J.
        Proliferation and apoptosis of hepatic stellate cells and effects of compound 861 on liver fibrosis.
        Chung Hua Kan Tsang Ping Tsa Chih. 2000; 8: 78-80
        • Yin C.
        • Ma H.
        • Wang A.
        • Ma X.
        • Jia J.
        • Wang B.
        Effect of compound 861 on tissue inhibitor of metalloprotenase 1 gene expression of HSC-T6 cells.
        Zhonghua Gan Zang Bing Za Zhi. 2002; 10: 197-199
        • Zhang F.
        • Wang B.
        • Wang T.
        • Jia J.
        • Dong Z.
        • Zhang J.
        Three-dimensional reconstruction of experimental fibrotic liver tissue and effect of herbal compound on it.
        Zhonghua Gan Zang Bing Za Zhi. 2000; 8: 355-357
        • Wang B.E.
        Treatment of chronic liver diseases with traditional Chinese medicine.
        J Gastroenterol Hepatol. 2000; 15: E67-E70
        • Batey R.
        • Cao Q.
        Effects of CH-100, a Chinese herbal medicine, on acute concanavalin A–mediated hepatitis in control and alcohol-fed rats.
        Alcohol Clin Exp Res. 2000; 24: 852-858
        • Batey R.G.
        • Bensoussan A.
        • Fan Y.Y.
        • Bollipo S.
        • Hossain M.A.
        Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C.
        J Gastroenterol Hepatol. 1998; 13: 244-247
        • Sama S.K.
        • Krishnamurthy L.
        • Ramachandran K.
        • Lal K.
        Efficacy of an indigenous compound preparation (Liv-52) in acute viral hepatitis—a double blind study.
        Indian J Med Res. 1976; 64: 738-742
        • Pandey S.
        • Gujrati V.R.
        • Shanker K.
        • Singh N.
        • Dhawan K.N.
        Hepatoprotective effect of LIV.52 against CCl4-induced lipid peroxidation in liver of rats.
        Indian J Exp Biol. 1994; 32: 694-697
        • Fleig W.W.
        • Morgan M.Y.
        • Holzer M.A.
        The ayurvedic drug LIV.52 in patients with alcoholic cirrhosis. Results of a prospective, randomized, double-blind, placebo-controlled clinical trial (abstr).
        J Hepatol. 1997; 26: 127
        • Salmi H.A.
        • Sarna S.
        Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study.
        Scand J Gastroenterol. 1982; 17: 517-521
        • Lucena M.I.
        • Andrade R.J.
        • de la Cruz J.P.
        • Rodriguez-Mendizabal M.
        • Blanco E.
        • Sanchez de la Cuesta F.
        Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study.
        Int J Clin Pharmacol Ther. 2002; 40: 2-8
        • Suzuki H.
        • Ohta Y.
        • Takino T.
        • Fujisawa K.
        • Hirayama C.
        Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis.
        Asian Med J. 1983; 26: 423-438
        • Tsubota A.
        • Kumada H.
        • Arase Y.
        • Chayama K.
        • Saitoh S.
        • Ikeda K.
        • Kobayashi M.
        • Suzuki Y.
        • Murashima N.
        Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection.
        Eur J Gastroenterol Hepatol. 1999; 11: 1077-1083
        • van Rossum T.G.
        • Vulto A.G.
        • Hop W.C.
        • Schalm S.W.
        Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C.
        Am J Gastroenterol. 2001; 96: 2432-2437